All News

Found 3,193 articles

• Telik, Inc. Reports Progress Toward Multiple Early Stage Milestones In The Development Of A Novel Antibody-Based Therapeutic Agent For Gastrointestinal Cancers

  8/28/2014

• Sorrento Therapeutics, Inc. Awarded National Institutes of Health (NIH) Grant to Advance Immunotherapy Targeting Idiopathic Pulmonary Fibrosis (IPF)

  8/26/2014

• Gallus Biopharmaceuticals, LLC Enters Agreement With Progenics Pharmaceuticals, Inc. For Manufacture Of Anti-PSMA Monoclonal Antibody

  8/21/2014

• Data Published By Researchers From The Scripps Research Institute Demonstrate Potential For MYC Inhibitor Licensed By Sorrento Therapeutics, Inc.

  8/18/2014

• Seattle Genetics, Inc. Initiates Phase 1 Clinical Trial Of Antibody-Drug Conjugate SGN-CD70A For Non-Hodgkin Lymphoma And Renal Cell Carcinoma

  8/12/2014

• Sorrento Therapeutics, Inc. Appoints Douglas Ebersole To Its Board Of Directors

  8/11/2014

• Progenics Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results

  8/8/2014

• ImmunoGen, Inc. Announces Webcast Of Presentations At Upcoming Investor Conferences

  8/5/2014

• ImmunoGen, Inc. Reports Fourth Quarter And Fiscal Year 2014 Financial Results

  8/1/2014

• Sorrento Therapeutics, Inc. The Unexpected Death Of Its Chief Business Officer

  8/1/2014

• Sorrento Therapeutics, Inc. Awarded Grant From The National Institutes of Health (NIH) For The Development Of A Small Molecule Myc Inhibitor

  7/21/2014

• ImmunoGen, Inc. Announces Conference Call To Discuss Its Fourth Quarter And Fiscal Year 2014 Financial Results

  7/18/2014

• Astellas Pharma Inc. Details Pipeline Progress At R&D Meeting

  7/11/2014

• Astellas Pharma Inc. Details Pipeline Progress At R&D Meeting

  7/11/2014

• Oxford BioTherapeutics Appoints Dr. Eugen Leo As Head Of Clinical Development

  7/8/2014

• Sorrento Therapeutics, Inc. Awarded Up To $2.6 Million From The National Institutes of Health (NIH) For The Development Of New Anti-Bacterial Bispecific Antibodies And Antibody Formulated Drug Conjugates

  7/1/2014

• Cambridge-Based Mersana Therapeutics, Inc. Strikes New Oncology Pact Worth $792 Million With Merck KGaA

  6/25/2014

• Morphotek Inc. And Sorrento Therapeutics, Inc. Sign An Exclusive Research And Option Agreement To Generate And Develop Morphotek Antibody Drug Conjugates

  6/25/2014

• Sorrento Therapeutics, Inc. Announces Confidential Submission Of Draft Registration Statement For Initial Public Offering (IPO) Of Its Wholly-Owned Subsidiary Ark Animal Health With The SEC

  6/23/2014

• Sorrento Therapeutics, Inc. To Present At Biotechnology Industry Organization (BIO) Business Forum

  6/23/2014